Castle Biosciences, Inc.
NASDAQ:CSTL · NASDAQ Global Market
+$0.04 today
Vol 0.71M · Avg 0.37M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-5.1%
avg 12.6%
ROIC
-6.8%
avg -28.9%
ROA
-4.2%
avg -20.8%
Analysis
ROA is currently the strongest return metric at -4.2% versus its period average of -20.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Derek J. Maetzold | Founder, Chief Executive Officer, President & Director | $1.81M | — | 64 | $91,881.00 | 0.30% |
Frank Stokes | Chief Financial Officer & Treasurer | $1.00M | — | 56 | $60,085.00 | 0.20% |
Kristen Oelschlager | Chief Operating Officer | $944,652.00 | — | 57 | $27,621.00 | 0.09% |
Tobin W. Juvenal | Chief Commercial Officer | $944,652.00 | — | 65 | $0.00 | <0.01% |
Kevin Doman | Vice President of Sales | — | — | — | — | — |
Trisha Poteet | Senior VP of Clinical Services & Manufacturing Operations | — | — | — | — | — |
Keli Greenberg | Vice President of Human Resources | — | — | — | — | — |
Camilla Zuckero | Vice President of Investor Relations & Corporate Affairs | — | — | — | — | — |
Jay Braxton | Vice President of Marketing & Brand Manager of Uveal Melanoma (UM) | — | — | — | — | — |
Matthew Goldberg | Senior Vice President of Medical | — | — | — | $11,766.00 | 0.04% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
87
$11.61M
Net Sentiment
$11.61M
Net selling
Most Active
MAETZOLD DEREK J
67 transactions
1–10 of 87
Analysis
Insiders reported 0 buys worth $0.00 and 87 sells worth $11.61M over the last 12 months. That adds up to net selling of $11.61M. MAETZOLD DEREK J was the most active insider with 67 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +60.4% | +20.6% (9yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +60.4% over three years. Forward estimates point to Revenue at +20.6% (9yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Vir Biotechnology, Inc.
NASDAQ:VIR
$1.54B
CareDx, Inc
NASDAQ:CDNA
$1.28B
AMN Healthcare Services, Inc.
NYSE:AMN
$1.20B
Personalis, Inc.
NASDAQ:PSNL
$887.60M
Geron Corporation
NASDAQ:GERN
$830.77M
Fulgent Genetics, Inc.
NASDAQ:FLGT
$512.49M
Evolent Health, Inc.
NYSE:EVH
$495.48M
Myriad Genetics, Inc.
NASDAQ:MYGN
$423.60M
Embecta Corp.
NASDAQ:EMBC
$184.05M
DarioHealth Corp.
NASDAQ:DRIO
$51.26M
Who manages CSTL?
Castle Biosciences, Inc. (CSTL) lists 10 active executives. The top listed executive is Frank Stokes, Chief Financial Officer & Treasurer.
Are CSTL insiders buying or selling?
Recent insider activity shows net selling of $15.95M.
Explore More
Continue the stock analysis
Jump to another research area for this company.